Chemical Structure (Pregabalin 01)
Pregabalin
Product Images NDC 75834-299
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 75834-299). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pregabalin 02)
This appears to be a table of data showing the percentage of patients who improved with different dosages of Pregabain for pain relief. It also includes a chart indicating the percentage of improvement in pain from the baseline.*
Figure 2 (Pregabalin 03)
The text describes a chart that indicates the percentage of patients who improved after taking Pregabalin 100 mg per day versus a placebo. It also shows the percentage improvement in pain from the baseline.*
Figure 3 (Pregabalin 04)
The text provides data on the percent of patients improved and their pain improvement from baseline using various dosages of Pregabalin and a placebo. The data is presented in numeric form, with some characters that are not readable. No further information is available to provide a more comprehensive description.*
Figure 4 (Pregabalin 05)
Figure 5 (Pregabalin 06)
The text describes the percent improvement in pain from baseline for patients in a clinical trial who received different doses of Pregabalin or a placebo. The doses used were 100mg and 50mg taken three times a day. The data is presented in a table format with numerical values under the headings "Pregatalin 100 mgthrestimes a day," "Pregatalin 50 mgthreatimes a day," and "Placebo." The heading "Percent Improvement in Pain from Baseline" accompanies the numerical values. The annotation "Peacent of Patients Improved" suggests that the numerical values represent the percentage of patients who experienced pain relief.*
Figure 6 (Pregabalin 07)
This is a chart showing the responder rates for different studies with different doses of a certain medication compared to placebo to determine its efficacy. The percentages represent the proportion of participants in each study who responded positively to the medication compared to placebo. The different doses of the medication are indicated on the right-hand side of the chart. The study with 600mg/day dose showed statistically significant results compared to placebo.*
Figure 7 (Pregabalin 08)
Figure 8 (Pregabalin 09)
The text shows the responder rate in percentage for different dosages of a drug and a placebo. The drug was administered at 2.5 mg/kg/day and 10 mg/kg/day. The percentage of respondents varies from 22.6% to 291%. The placebo group had a responder rate of 40.6%.*
Figure 9 (Pregabalin 10)
The text provides data on the percentage of patients improved using different daily doses of pregabalin and Phceto medication. It also shows the percentage of improvement in pain from baseline.*
Figure 10 (Pregabalin 11)
This appears to be a table or a list with values that seem to indicate estimated percentages of subjects without something referred to as "LTR", with various percentages ranging from 0% to 100%. There are also numbers at the end that may or may not be related to the percentages. However, without more context or information, it is not possible to determine the meaning or usefulness of this data.*
Figure 11 (Pregabalin 12)
This is a table showing the percentage of subjects who improved from baseline at Week 12 using Pregabalin and Placebo. It does not provide any further information on the study design, methods or results.*
Figure 12 (Pregabalin 13)
The text is a chart showing the percent of subjects who improved from baseline to week 18 BOCF for a drug called Pregabalin - cevo. The chart includes values on the x-axis and percent improved on the y-axis. The drug resulted in 100% of subjects improving.*
Principal Display Panel (25 mg Capsule Bottle Label)
This is a description of Pregabalin medication contained in a pack of 60 capsules. The pharmacist is instructed to dispense a medication guide to each patient for usage. The usual dosage should be in accordance with the accompanying prescribing information, and each capsule contains 26mg of Regabaln, USP. The permission to store should be between 15° to 30° C (59° to 85°F), and the manufacturer's details are listed as SICF and Eskayef Pharmaceuticals Limited, with an address in Bangladesh.*
Principal Display Panel (50 mg Capsule Bottle Label)
This is a description for a medication with the NDC code 75834-207-60. Each capsule of the medication contains 50 mg of pregabalin, USP. The medication is dispensed in a child-resistant container and the usual dosage should be determined by a prescribing physician. The medication should be stored at a temperature between 20° and 26°C, with permitted excursions between 15° and 30°C. The medication should be dispensed with a medication guide to each patient. The medication is manufactured by ESKAYEF PHARMACEUTICALS LIMITED in Bangladesh and distributed by Nivagen Pharmaceuticals, Inc. There are 60 capsules per container, and the manufacturer's license number is 449.*
Principal Display Panel (75 mg Capsule Bottle Label)
This is a medication description for Pregabalin capsules with a concentration of 76 mg, manufactured by ESKAYEF PHARMAGEUTIGALS LINITED in Bangladesh. The prescription medication comes in a bottle of 60 capsules and is dispensed with an accompanying medication guide. The recommended dosage is indicated in the prescribing information, and the medication should be stored within a temperature range of 20°C to 25°C. The NDC code for this medication is NDG 75634-29860.*
Principal Display Panel (100 mg Capsule Bottle Label)
This is a description of a medication called Pregabalin provided in 60 capsules per bottle. Each capsule of the medication contains 100 mg of Pregabalin USP. The medication should be dispensed only with the accompanying prescription information, and in a tightly sealed container to ensure potency. The recommended dosage information is given with the accompanying prescription information. The manufacturer of the medication is ESKAYEF PHARNAGEUTICALS LIMITED located in Bangladesh, and the medication is made for Nivagen Pharmaceuticals in the United States. The medication should be stored at a temperature ranging from 20°C to 25°C (68°F to 77°F).*
Principal Display Panel (150 mg Capsule Bottle Label)
This is a description of a medication package containing 60 capsules of Pregabalin, with each capsule containing 150mg of the drug. The package also includes an accompanying medication guide that should be given to the patient by the pharmacist. The packaging suggests that the medicine should be dispensed in tight, child-resistant containers and stored at temperatures between 15°-30°C (59°-86°F). The drug was manufactured by SK-F Eskayef Pharmaceuticals Limited in Bangladesh and is being distributed in the United States by Nivagen Pharmaceuticals, Inc. Prescription is required to obtain this medication.*
Principal Display Panel (200 mg Capsule Bottle Label)
This is a medication consisting of 60 capsules, each containing 200 mg pregabain, USP, used for treating neuropathic pain, fibromyalgia, anxiety and certain types of seizures. The capsules should be stored at room temperature between 20° to 25°C in a child-resistant container, and a pharmacist should dispense the accompanying medication guide to each patient. The medicine is manufactured by Eskayef Pharmaceuticals Limited located in Bangladesh, and distributed by Nivagen Pharmaceuticals, Inc. in Sacramento, CA, USA.*
Principal Display Panel (225 mg Capsule Bottle Label)
This is a medication label for a package of 60 capsules of pregabalin, which contains 225 mg. The dosage instruction and the prescription are not available, and it is recommended to store the capsules at a controlled temperature. The label also indicates the manufacturer and their address in Bangladesh.*
Principal Display Panel (300 mg Capsule Bottle Label)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
